Gore S M, Fontaine O, Pierce N F
Medical Research Council, Biostatistics Unit, Cambridge.
BMJ. 1992 Feb 1;304(6822):287-91. doi: 10.1136/bmj.304.6822.287.
To define the benefit of rice oral rehydration salts solution in relation to the glucose based World Health Organisation oral rehydration salts solution for treating and preventing dehydration in patients with severe dehydrating diarrhoea.
Meta-analysis using data from 13 available randomised trials that compared these two formulations.
The studies compared 1367 patients with cholera, severe cholera-like diarrhoea, or acute non-cholera diarrhoea. 668 received the standard WHO solution and 699 the rice based solution.
Each trial report was reviewed to determine patient eligibility, the number of patients who were randomised and the number of these excluded from analysis, details of the randomisation procedure, and the precise timing of the outcome measurements.
Stool output during the first 24 hours; weighted estimates of the difference in mean stool output between treatments.
The rice solution significantly reduced the rate of stool output during the first 24 hours by 36% (95% confidence interval 28 to 44%) in adults with cholera and by 32% (19 to 45%) in children with cholera. The rate of stool loss in infants and children with acute non-cholera diarrhoea was reduced by only 18% (6 to 30%).
The benefit of rice oral rehydration salts solution for patients with cholera is sufficiently great to warrant its use in such patients. The benefit is considerably smaller for children with acute, noncholera diarrhoea and should be more precisely defined before its practical value can be judged.
确定大米口服补液盐溶液相对于基于葡萄糖的世界卫生组织口服补液盐溶液在治疗和预防严重脱水腹泻患者脱水方面的益处。
使用来自13项现有随机试验的数据进行荟萃分析,这些试验比较了这两种配方。
这些研究比较了1367例霍乱、严重霍乱样腹泻或急性非霍乱腹泻患者。668例接受标准的世界卫生组织溶液,699例接受大米基溶液。
对每份试验报告进行审查,以确定患者的入选标准、随机分组的患者数量以及从分析中排除的患者数量、随机分组程序的细节以及结果测量的精确时间。
头24小时内的粪便排出量;治疗之间平均粪便排出量差异的加权估计值。
大米溶液在霍乱成人患者中显著降低了头24小时内的粪便排出率36%(95%置信区间28%至44%),在霍乱儿童中降低了32%(19%至45%)。急性非霍乱腹泻婴幼儿和儿童的粪便丢失率仅降低了18%(6%至30%)。
大米口服补液盐溶液对霍乱患者的益处足够大,值得在这类患者中使用。对急性非霍乱腹泻儿童的益处要小得多,在判断其实际价值之前应更精确地确定。